Navigation Links
Ferring to Highlight Phase 3 Data for Cervical Ripening Candidate at Society for Maternal-Fetal Medicine Annual Meeting
Date:2/12/2013

SAN FRANCISCO, Feb. 12, 2013 /PRNewswire/ -- Ferring Pharmaceuticals will present pivotal Phase 3 efficacy and safety data from its EXPEDITE* study for its investigational controlled release misoprostol vaginal insert (MVI) at the 33rd annual meeting of the Society for Maternal-Fetal Medicine (SMFM) in San Francisco, February 11 - 16. These and other research findings formed the basis for Ferring's New Drug Application (NDA) to the U.S. Food and Drug Administration (FDA) supporting the use of the controlled release MVI as a treatment option for cervical ripening as part of the labor induction process.

Studies accepted for presentation include

  • An oral presentation on Sat., Feb. 16 (9 a.m. – 9:15 a.m. PST), titled "Efficacy and safety of misoprostol vaginal insert compared with dinoprostone vaginal insert for labor induction" (lead author: Deborah A. Wing , MD, University of California, Irvine); and
  • A poster presentation on Thurs., Feb. 14 (3:30 p.m. – 5:30 p.m. PST), titled "Comparison of misoprostol vaginal insert and dinoprostone vaginal insert: incidence of treatment-emergent adverse events" (lead author: Stacey Ehrenberg-Buchner , MD, University of Michigan Health System).

*The EXPEDITE Study: A Phase 3, double blind, randomized, multicenter study of exogenous prostaglandin comparing the efficacy and safety of the misoprostol vaginal insert (MVI) 200 mcg to the dinoprostone vaginal insert for reducing time to vaginal delivery in pregnant women at term.

For further information, contact:
Leila Boukassi
MSL New York
leila.boukassi@mslgroup.com; 646.500.7735 

About Ferring Pharmaceuticals:
Ferring Pharmaceuticals is a research-driven speciality biopharmaceutical company, active in global markets. The company identifies, develops and markets innovative products in the areas of general and pediatric endocrinology, gastroenterology, infertility, obstetrics/gynecology, orthopedics and urology. For more information, call 1-888-FERRING (1-888-337-7464) or visit www.FerringUSA.com.

 


'/>"/>
SOURCE Ferring Pharmaceuticals
Copyright©2012 PR Newswire.
All rights reserved

Related medicine technology :

1. ESTEVE Fosters R & D by Transferring its Center for Drug Discovery to the Science Park of Barcelona (PCB)
2. Ferring Pharmaceuticals Inc. Named 10th Fastest Growing New Jersey Company
3. Ferring Pharmaceuticals Inc. Recognized for Best-in-Class Work-Life Portfolio
4. Zacks Industry Outlook Highlights: Eli Lilly, Forest Labs, ViroPharma, Novartis and United Therapeutics
5. Staffing and Performance Benchmarks for Quality Function Highlight New Medical Device Study
6. Isis Reports Financial Results and Highlights for First Quarter 2012
7. Delcath Highlights First Quarter 2012 And Recent Accomplishments
8. Soligenix Reports First Quarter 2012 Financial Results and Highlights Recent Accomplishments
9. Volcano to Highlight its Leadership in Precision Guided Therapy at EuroPCR 2012
10. "Emergency Medical Services Week" Highlights Stroke Survivors and Awareness
11. PharMEDium Highlights Enhanced Labeling for ICU Services at Critical Care Expo
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/23/2016)... HILLS, Calif. , June 23, 2016 Any ... the many challenges of the current process. Many of them ... because of the technical difficulties and high laboratory costs involved. ... have to offer it at such a high cost that ... afford it. Dr. Parsa Zadeh , founder ...
(Date:6/23/2016)... , June 23, 2016 ... CAPR ), a biotechnology company focused on the ... announced that patient enrollment in its ongoing randomized ... has exceeded 50% of its 24-patient target. Capricor ... the third quarter of 2016, and to report ...
(Date:6/23/2016)... -- Astellas today announced the establishment of Astellas Farma Colombia (AFC), a new affiliate with operations headquartered in ... . ... ... ... Astellas is ...
Breaking Medicine Technology:
(Date:6/25/2016)... ... June 25, 2016 , ... Austin residents seeking Mohs ... College of Mohs Surgery and to Dr. Russell Peckham for medical and surgical dermatology. ... treatment for skin cancer. The selective fellowship in Mohs Micrographic Surgery completed by Dr. ...
(Date:6/25/2016)... City, Oklahoma (PRWEB) , ... June 25, 2016 ... ... helping both athletes and non-athletes recover from injury. Recently, he has implemented orthobiologic ... the Oklahoma City area —Johnson is one of the first doctors to perform ...
(Date:6/24/2016)... ... ... June 19, 2016 is World Sickle Cell Observance Day. In an effort to ... treatments, Serenity Recovery Center of Marne, Michigan, has issued a pain management ... (SCD) is a disorder of the red blood cells, which can cause episodes of ...
(Date:6/24/2016)... ... June 24, 2016 , ... Comfort Keepers® of San Diego, CA is ... Road To Recovery® program to drive cancer patients to and from their cancer treatments. ... the highest quality of life and ongoing independence. Getting to and from medical ...
(Date:6/24/2016)... Vegas, Nevada (PRWEB) , ... June 24, 2016 ... ... Las Vegas client, The Grove Investment Group (TGIG), has initiated cultivation and processing ... Grove, in Las Vegas and Pahrump, Nevada. , Puradigm is the manufacturer of ...
Breaking Medicine News(10 mins):